Covalent biologics: a new class of drugs on the horizon
The budding field of covalent biologics has made headway recently, as the only biotech pioneering the space has bagged $100 million in funding to move its pipeline to the clinic. American company Enlaza Therapeutics’ undisclosed preclinical pipeline is …